Having trouble viewing the email? click here.

To all of the eHV community – team, partners, collaborators, entrepreneurs, friends.

Spring is here and we want to wish you all a Happy Passover – filled with renewal, togetherness and joy.

We just held our annual innovation contest, together with the Morris Kahn and Maccabi Research and Innovation Institute and we would like to this opportunity to tell you about the partnership, the event and the winner.

Also – we’re welcoming an additional company (No. 6!) into the incubator so we are definitely doing our share of “growth and renewal” for the spring season.

Stay in touch and please stop by to visit us – the spring is beautiful around here…

The eHealth Ventures Team

eHealth Ventures partners with MK&M Research and Innovation Institute to hold Annual Innovation contest
On March 20th, over 180 people attended the annual innovation contest held at Tel Aviv University. The topic this year was Big Data in Digital Health and we partnered with the ideal entity for this: the MK&M institute is owner of the largest medical / patient databases in the world – over 2 M patients for over 20 years of data (!). Almost 30 companies applied and 5 promising and innovative candidates were selected for the final (the finalist selection was by eHV partners worldwide – including Amgen and Cleveland Clinic representatives).
The finalists (by order of presentation) were:
NeuroCan – Automated interpretation of EEG output
ImmunArray – Decoding the immune system and allowing better diagnosis
ACA Fetal HR – AI for interpretation and analytics of Digital fetal monitor readouts
SensPD – A novel system for early detection of Autism
EfA – Developing a handheld “Lab on a Chip” device

The audience also enjoyed top level keynote speeches, a Telepathy artist, good food and wine, and of course - great content and networking.

We hope to see you there next year!!

MK&M Research & Innovation Institute
Morris Kahn and Maccabi Research and Innovation Institute was established in 2016, unifying previously existing research units at Maccabi with novel ones. The institute's vision is to lead in big data analytics and innovation for the improvement of precision medicine and increase the amount and quality of medical research being performed at any given moment in Israel and worldwide.  
The Institute has developed a state of the art big data platform, enabling online access world to Maccabi's database for researchers all around the world. The platform enables predictive analysis research using advanced machine algorithms. In addition, the data gathered in Maccabi is enriched so that new and innovative uses to free text, images and pathology scans can be realized. As an example, of the projects deals with digitalizing and analyzing pathologies in the area of cancer in general and specifically prostate cancer.
The institute is able to create these remarkable breakthroughs utilizing the unique partnership with Maccabi - its professional abilities and wealth of data, and an intensive cooperation with leading multinationals in the technological and pharmaceutical industries, as well as by tapping into Israel's ecosystem providing us with the access to the start-up nation’s best and brightest minds.
The Institute's core activities include:
  • Database research
  • Big data research (including non-structured data such as Image and voice)
  • Clinical studies
  • Biological bank
The Winner of the 2018 Innovation Contest is: EfA – Engineering for All
The company, founded and managed by Yoel Ezra, is developing RevDx© - a revolutionary diagnostic system - From a finger prick to fully automated on-the-spot accurate diagnostics and real-time disease mapping.

RevDx is designed to be an affordable handheld real-time digital multichannel diagnostic and disease mapping solution for integrated community case management to everyone, everywhere. 

A new company to be accepted into the eHV incubator: Sensogenic Ltd.
We are happy and proud to announce the launch of our newest Incubator company: Sensogenic.
SensoGenic was founded by alon Yasovsky and is developing a device that can detect minimal amounts (1-3 PPM) of a respiratory or food allergen using molecular technology based on fixing a low-cost and sensitive molecular compound to QCM (Quartz Crystal Microbalance), which enables high sensitivity to the presence of the allergens.

The technology is based on an internal sensor which will have a proprietary disposable head component (50-100 tests). The co. has already filed IP of the molecular biosensor system and is working on a proprietary online algorithm for the allergen analysis. It will own a database of the user’s food habits: where, when, what you eat, thus having a potential of providing data analytics (food habits) for up to 5$ per user per month.
To change your subscription, click here.